Cadila Healthcare is currently trading at Rs. 529.70, up by 4.60 points or 0.88% from its previous closing of Rs. 525.10 on the BSE.
The scrip opened at Rs. 533.00 and has touched a high and low of Rs. 535.35 and Rs. 527.45 respectively. So far 38470 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 305.05 on 24-Jun-2016.
Last one week high and low of the scrip stood at Rs. 538.10 and Rs. 513.75 respectively. The current market cap of the company is Rs. 54099.68 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.14% and 8.07% respectively.
Cadila Healthcare has received an approval to raise funds through various sources. The board of directors at its meeting held on June 26, 2017 has approved for the same. The board has approved to raise funds by issue of Equity Shares / convertible Bonds / Debentures through Qualified Institutional Placement [QIP] / GDR / ADR, for an aggregate amount up to Rs 10,000 crore.
Besides, the board also approved to issue Secured / Unsecured Redeemable Non-Convertible Debentures / Foreign Currency Bonds on Private Placement Basis for an amount up to Rs 3,500 crore in the Financial Year 2017-2018 and to issue Foreign Currency Bond / Foreign Currency Convertible Bonds.
Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: